内容紹介
Three Poor Performance Status(PS)Cases of Metastatic Breast Cancer Controlled with Adjustment of Dosing Interval and Dosage of Bevacizumab and Paclitaxel
Summary
A standard symptomatic therapy regimen of bevacizumab(BV)plus paclitaxel(PTX)was planned for use in 3 cases of metastatic breast cancer. Due to poor patient performance status(PS)because of malignant pleural effusion and ascites, the initial standard regimen was determined to be unsuitable. However, adjustment and fine-tuning of the BV plus PTX interval and dosage were found to be effective in improving symptoms, and consequently obtained good efficacy. Adverse effects were managed with drug withdrawal and symptomatic therapy. The 3 clinical cases all included females aged 62-76 years old, with a median age of 67.6. One case was classified as PS 3, and 2 were classified as PS 4. The main deciding factors for initiating the regimen of BV plus PTX were 2 cases of malignant pleural effusion and 1 case of malignant ascites, which contributed to worsening of the overall PS. With adjustment and fine-tuning of the BV plus PTX interval and dosage, we were able to safely achieve symptomatic improvement in 3 metastatic breast cancer cases, in which the overall PS grade was unsuitable for standard chemotherapy.
要旨
症例は胸水や腹水貯留によりperformance status(PS)不良の進行再発乳癌3症例。症状コントロールの目的でbevacizumab(BV)+paclitaxel(PTX)療法を施行する方針としたが,PS不良のため標準用量不適と判断し,BV+PTXの用法・用量を減じて投与したが有効であった。有害事象は休薬・対症療法にて十分コントロール可能であった。3症例の年齢中央値は67.6 (62～76) 歳, PSはPS 3が1例, PS 4が2例であった。 BV+PTX投与開始の原因となった病態は, 3例中2例が癌性胸水,1例が癌性胸水と癌性腹水であり,いずれもPSを悪化させる要因となっていた。通常は化学療法の適応とならないPS不良症例に対しても,BV+PTXを用法・用量を減じて投与することで安全に症状緩和を図ることが可能であった。
目次
Summary
A standard symptomatic therapy regimen of bevacizumab(BV)plus paclitaxel(PTX)was planned for use in 3 cases of metastatic breast cancer. Due to poor patient performance status(PS)because of malignant pleural effusion and ascites, the initial standard regimen was determined to be unsuitable. However, adjustment and fine-tuning of the BV plus PTX interval and dosage were found to be effective in improving symptoms, and consequently obtained good efficacy. Adverse effects were managed with drug withdrawal and symptomatic therapy. The 3 clinical cases all included females aged 62-76 years old, with a median age of 67.6. One case was classified as PS 3, and 2 were classified as PS 4. The main deciding factors for initiating the regimen of BV plus PTX were 2 cases of malignant pleural effusion and 1 case of malignant ascites, which contributed to worsening of the overall PS. With adjustment and fine-tuning of the BV plus PTX interval and dosage, we were able to safely achieve symptomatic improvement in 3 metastatic breast cancer cases, in which the overall PS grade was unsuitable for standard chemotherapy.
要旨
症例は胸水や腹水貯留によりperformance status(PS)不良の進行再発乳癌3症例。症状コントロールの目的でbevacizumab(BV)+paclitaxel(PTX)療法を施行する方針としたが,PS不良のため標準用量不適と判断し,BV+PTXの用法・用量を減じて投与したが有効であった。有害事象は休薬・対症療法にて十分コントロール可能であった。3症例の年齢中央値は67.6 (62～76) 歳, PSはPS 3が1例, PS 4が2例であった。 BV+PTX投与開始の原因となった病態は, 3例中2例が癌性胸水,1例が癌性胸水と癌性腹水であり,いずれもPSを悪化させる要因となっていた。通常は化学療法の適応とならないPS不良症例に対しても,BV+PTXを用法・用量を減じて投与することで安全に症状緩和を図ることが可能であった。